Louis G. Lange - 29 Dec 2023 Form 3 Insider Report for NewAmsterdam Pharma Co N.V. (NAMS)

Role
Director
Signature
/s/ Louise Kooij by Power of Attorney for Louis G. Lange
Issuer symbol
NAMS
Transactions as of
29 Dec 2023
Net transactions value
$0
Form type
3
Filing time
29 Dec 2023, 16:30:10 UTC
Previous filing
04 Oct 2022
Next filing
03 Jan 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding NAMS Ordinary Shares 9,878 29 Dec 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding NAMS Option (right to buy) 29 Dec 2023 Ordinary Shares 57,583 $10.90 Direct F1
holding NAMS Option (right to buy) 29 Dec 2023 Ordinary Shares 94,835 $10.00 Direct F2
holding NAMS Option (right to buy) 29 Dec 2023 Ordinary Shares 75,351 Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option was granted on January 1, 2023. 25% of the shares underlying the option will vest on the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date.
F2 The option was granted on November 22, 2022. The shares underlying the option vest in equal monthly installments over four years, with the first 1/48th of such shares vesting on December 1, 2022 and the remaining installments vesting on each one-month anniversary of the grant date, subject to the Reporting Person's continued service through each such date.
F3 The option was granted on November 22, 2022 to replace an option originally granted on July 8, 2021 which was cancelled in connection with the consummation of NewAmsterdam Pharma Company N.V.'s business combination with Frazier Lifesciences Acquisition Corporation. 25% of the shares underlying the option vested on June 1, 2022, the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date. 9,878 shares underlying the option have been exercised by the Reporting Person.
F4 The exercise price of the option is Euro 1.16392.

Remarks:

Exhibit List: Exhibit 24.1 - Power of Attorney